AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Bacterial Infections: Enoxacin is used to treat various bacterial infections, including urinary tract infections (UTIs), respiratory tract infections, skin and soft tissue infections, bone and joint infections, and sexually transmitted infections (STIs) such as gonorrhea.
Gram-Negative and Gram-Positive Coverage: Enoxacin exhibits activity against both Gram-negative and Gram-positive bacteria. It can target pathogens such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Staphylococcus aureus, Streptococcus pneumoniae, and others.
UTIs and Prostatitis: Enoxacin is particularly effective in treating urinary tract infections, including complicated and uncomplicated UTIs, as well as prostatitis (inflammation of the prostate gland) caused by susceptible bacteria.
Respiratory Infections: It can be used to treat respiratory tract infections, including bronchitis and pneumonia caused by susceptible bacteria.
Skin and Soft Tissue Infections: Enoxacin may be prescribed for skin and soft tissue infections, such as cellulitis and wound infections, when caused by susceptible organisms.
Bone and Joint Infections: In some cases, enoxacin can be used to treat bone and joint infections caused by susceptible bacteria, although it may not be the first-line choice for these infections.
Gonorrhea: Enoxacin was previously used to treat gonorrhea, but its use has decreased due to the emergence of resistant strains. It may still be effective against some gonorrhea strains in regions where resistance rates are low.
Side Effects: Like other fluoroquinolone antibiotics, enoxacin can cause various side effects, including gastrointestinal symptoms (nausea, vomiting, diarrhea), central nervous system effects (headache, dizziness, insomnia), and musculoskeletal effects (tendonitis, tendon rupture). Rare but serious adverse effects include peripheral neuropathy, hypersensitivity reactions, and potentially irreversible damage to tendons, muscles, joints, nerves, and the central nervous system.
Drug Interactions: Enoxacin may interact with other medications, including antacids, sucralfate, iron supplements, and certain anticoagulants, potentially reducing its absorption or efficacy.
Precautions: Enoxacin should be used with caution in patients with a history of seizures, renal impairment, myasthenia gravis, or other neurological disorders. It is generally not recommended for use in children, pregnant women, or breastfeeding mothers unless the benefits outweigh the risks.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.7 | 0.6 | 6.83 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 2.7 | 0.26 |
| Allergies | 6.9 | 3.3 | 1.09 |
| Allergy to milk products | 2.2 | 1.6 | 0.38 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.7 | 8.3 | -0.24 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.3 | 1.1 | 2 |
| Ankylosing spondylitis | 4.9 | 1.8 | 1.72 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 2.1 | 0.3 | 6 |
| Asthma | 6.3 | 2.4 | 1.63 |
| Atherosclerosis | 2.7 | 2.1 | 0.29 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 11.1 | 10.4 | 0.07 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 3 | 3 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.9 | 2.9 | -2.22 |
| Carcinoma | 4.9 | 2.6 | 0.88 |
| Celiac Disease | 3.6 | 3.7 | -0.03 |
| Cerebral Palsy | 1.5 | 1.3 | 0.15 |
| Chronic Fatigue Syndrome | 6.6 | 7.7 | -0.17 |
| Chronic Kidney Disease | 5.2 | 3 | 0.73 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 3 | 2 | 0.5 |
| Chronic Urticaria (Hives) | 2 | 1.4 | 0.43 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 8.5 | 2.8 | 2.04 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 3 | 3 | 0 |
| COVID-19 | 10.7 | 13 | -0.21 |
| Crohn's Disease | 10 | 5.9 | 0.69 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.6 | -0.33 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.8 | 1.4 | 1 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 13.1 | 10.6 | 0.24 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.3 | 0 |
| Endometriosis | 3.5 | 2.6 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.1 | 2.1 | 0.95 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 3.1 | 2.6 | 0.19 |
| Functional constipation / chronic idiopathic constipation | 6.7 | 4.9 | 0.37 |
| gallstone disease (gsd) | 4.3 | 1.2 | 2.58 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.5 | 1.9 | 0.84 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.2 | 0.6 | 2.67 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.8 | -1 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4 | 1.9 | 1.11 |
| Heart Failure | 5.1 | 2 | 1.55 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 0.2 | 4.5 |
| hyperglycemia | 3 | 1.5 | 1 |
| Hyperlipidemia (High Blood Fats) | 1 | 0.3 | 2.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5 | 5.7 | -0.14 |
| Hypothyroidism | 0.1 | 1 | -9 |
| Hypoxia | 3.7 | 0.3 | 11.33 |
| IgA nephropathy (IgAN) | 1.9 | 5.2 | -1.74 |
| Inflammatory Bowel Disease | 10 | 10.9 | -0.09 |
| Insomnia | 2.5 | 2.8 | -0.12 |
| Intelligence | 2 | 0.6 | 2.33 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 9.3 | 5.6 | 0.66 |
| ischemic stroke | 3 | 1.7 | 0.76 |
| Liver Cirrhosis | 8.8 | 5.2 | 0.69 |
| Long COVID | 7.8 | 8.2 | -0.05 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.2 | 0.25 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.7 | 0.7 | 1.43 |
| Metabolic Syndrome | 9.1 | 8.4 | 0.08 |
| Mood Disorders | 12.8 | 8.5 | 0.51 |
| multiple chemical sensitivity [MCS] | 1.3 | 0.1 | 12 |
| Multiple Sclerosis | 8 | 6.7 | 0.19 |
| Multiple system atrophy (MSA) | 1.5 | 0.7 | 1.14 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.2 | -9.67 |
| Neuropathy (all types) | 0.8 | 2.2 | -1.75 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.9 | 4.7 | 0.26 |
| NonCeliac Gluten Sensitivity | 1.5 | 0.6 | 1.5 |
| Obesity | 12.1 | 9.6 | 0.26 |
| obsessive-compulsive disorder | 7 | 4.5 | 0.56 |
| Osteoarthritis | 2.7 | 1.3 | 1.08 |
| Osteoporosis | 2.5 | 1.5 | 0.67 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 9.8 | 7.7 | 0.27 |
| Polycystic ovary syndrome | 7.9 | 3.3 | 1.39 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 4 | 3.6 | 0.11 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9 | 4.7 | 0.91 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7 | 3.2 | 1.19 |
| scoliosis | 0.9 | 0.9 | 0 |
| Sjögren syndrome | 3.2 | 3 | 0.07 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.2 | 0.4 | 4.5 |
| Stress / posttraumatic stress disorder | 3.3 | 3 | 0.1 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1 | 0.3 | 2.33 |
| Type 1 Diabetes | 4.7 | 3.9 | 0.21 |
| Type 2 Diabetes | 10.1 | 8 | 0.26 |
| Ulcerative colitis | 6.4 | 8.1 | -0.27 |
| Unhealthy Ageing | 6.8 | 2.6 | 1.62 |
| Vitiligo | 2.5 | 1.6 | 0.56 |
